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https://doi.org/10.1016/j.celrep.2021.109153SUMMARYThe ATPase p97 is a central component of the ubiquitin-proteasome degradation system. p97 uses its
ATPase activity and co-factors to extract ubiquitinated substrates from different cellular locations, including
DNA lesions, thereby regulating DNA repair pathway choice. Here, we find that p97 physically and function-
ally interacts with the MRE11-RAD50-NBS1 (MRN) complex on chromatin and that inactivation of p97 blocks
the disassembly of the MRN complex from the sites of DNA damage upon ionizing radiation (IR). The inhibi-
tion of p97 function results in excessive 50-DNA end resection mediated by MRE11 that leads to defective
DNA repair and radiosensitivity. In addition, p97 inhibition by the specific small-molecule inhibitor CB-
5083 increases tumor cell killing following IR both in vitro and in vivo. Mechanistically, this is mediated via
increased MRE11 nuclease accumulation. This suggests that p97 inhibitors might be exploited to improve
outcomes for radiotherapy patients.INTRODUCTION
Cancer cells are under continuous proteotoxic stress from aggre-
gated and misfolded proteins due to an increased number of
chromosomes and point mutations in protein-coding sequences.
This makes tumors strongly dependent on protein degradation
pathways for survival (Guang et al., 2019; Deshaies, 2014). The
ubiquitin-proteasome system (UPS) is responsible for most of
the protein degradation in mammalian cells and represents over
19% of mutated cancer driver genes (Collins and Goldberg,
2017; Tokheim et al., 2021). Dysregulation of the UPS is involved
in nearly all cancer hallmarks (Hanahan andWeinberg, 2011). The
AAA+ ATPase p97, also known as valosin-containing protein
(VCP), is the central component of the UPS. Its overexpression
has been demonstrated in various tumors (Tsujimoto et al.,
2004; Yamamoto et al., 2004a, 2004b, 2004c), implying that
both the UPS and p97 are necessary for cancer cell survival
through the maintenance of protein homeostasis.
p97, with the aid of a plethora of co-factors that contain
specialized domains to bind ubiquitinated proteins, extracts
ubiquitinated substrates from different cellular locations. Such
extracted ubiquitinated proteins are prepared for degradation
or recycled (van den Boom and Meyer, 2018; Dantuma and
Hoppe, 2012; Stolz et al., 2011). Previous work on the role ofThis is an open access article undp97 in cancer has largely focused on its cytoplasmic func-
tions, mainly the endoplasmic-reticulum-associated degrada-
tion pathway (Anderson et al., 2015; LeMoigne et al., 2017; Stolz
et al., 2011). However, accumulating evidence has demon-
strated a role for p97 in disassembly/removal of ubiquitinated
proteins from chromatin (Moreno et al., 2014; Franz et al.,
2016; Cao et al., 2003; Ramadan et al., 2007; Hirsch et al.,
2009). Similarly, p97 regulates DNA double-strand break (DSB)
repair by affecting repair pathway choice (Kuo et al., 2016; van
den Boom et al., 2016; Meerang et al., 2011; Acs et al., 2011).
p97 has a function in both main DSB pathways, homologous
recombination (HR) and non-homologous end joining (NHEJ).
For example, p97 removes ubiquitinated KU80 from broken
DNA ends, thus promoting HR over NHEJ (van den Boom
et al., 2016). Conversely, p97 removes the main DNA damage
response (DDR) ubiquitin ligase RNF8 from DSB sites, thereby
promoting NHEJ (Singh et al., 2019).
The MRE11-RAD50-NBS1 (MRN) complex has a critical role in
the initial processingofDSBends forefficientHRrepair. Theendo-
nuclease and 30-50 exonuclease activities of MRE11 resect dou-
ble-stranded DNA (dsDNA) and create 30 single-stranded DNA
(ssDNA), an essential DNA structure for HR repair, in S/G2 phase
of the cell cycle (Paull, 2018; Nieminuszczy et al., 2019). Resected
DNA ends can also be processed by alternative pathways that areCell Reports 35, 109153, May 25, 2021 ª 2021 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESSinherently mutagenic, namely, alternative NHEJ (alt-NHEJ) and
single-strand annealing (SSA) (Ceccaldi et al., 2016; Bhargava
et al., 2016). Various proteins, including UBQLN4, DYNLL1, and
C1QBP, regulateMRE11activity onchromatin (Bai et al., 2019; Ja-
chimowicz et al., 2019; He et al., 2018). For example, UBQLN4
remodels the MRN complex to curtail DSB end resection by con-
trollingMRE11’s associationwith chromatin and removing ubiqui-
tinated MRE11 from damaged chromatin. One of the functions of
MRN remodeling is to control MRE11 nuclease activity, because
both decreased and excessiveMRE11 nuclease activity compro-
mises error-free DSB repair (Hashimoto et al., 2010; Ray Chaud-
huri et al., 2016; Schlacher et al., 2011).
Here, we show that p97 interacts with and removes MRE11
from chromatin, thereby controlling MRE11-mediated 50-DNA
end resection after IR. Furthermore, inactivation of p97 ATPase
activity results in an accumulation of MRE11 on chromatin after
IR. This leads to an increase in ssDNA generation and a DNA
repair template switch from error-free RAD51-mediated HR to
RAD52-mediated SSA. We therefore postulate that p97-medi-
ated regulation of MRE11 on chromatin is essential for DSB
repair pathway choice, 53BP1 foci formation, and cell survival.
Indeed, increased DNA end resection and radiosensitivity in
p97-inactivated cells were alleviated by inactivating MRE11
nuclease activity. Finally, using bladder cancer as a model sys-
tem,we demonstrate that inhibition of p97 byCB-5083 increases
tumor cell killing after IR and suppresses xenograft tumor
growth, without additional toxicity to surrounding normal tissues
in the mouse model used. This suggests that the here-discov-
ered p97-MRE11 axis could potentially be targeted clinically to
achieve radiosensitization and improve tumor cure in patients,
especially in those with elevated levels of p97 protein.
RESULTS
p97 is required for MRE11 turnover on chromatin and
DNA damage
p97 has many interaction partners and co-factors required for its
diverse cellular functions (Schuberth and Buchberger, 2008;Figure 1. p97 is required for MRE11 turnover on chromatin and DNA d
(A) Schematic of SILAC-based mass spectrometry screen for p97 interactome a
(B) Illustrative graph based on the schematic in (A), showing SILAC ratio of p97 a
(C) Mass spectrometry analysis of the MRE11 interactome identifies RAD50, NB
(D) p97 interacts with the MRE11-RAD50-NBS1 (MRN) complex in chromatin f
absence of the p97 inhibitor CB-5083 (10 mM) and IR (10 Gy); n = 2.
(E) Doxycycline (DOX)-inducible HEK293 Flip-In p97-EQ-Strep-tag cells were exp
p97-EQ-Strep; n = 2.
(F) Endogenous p97was immunoprecipitated with p97-specific immunoglobulin G
on chromatin in the presence or absence of IR (10 Gy).
(G) Representative images of the number of MRE11 foci at 4 h of recovery after
(H) Quantifications of MRE11 foci in T24 cells after 2 Gy IR in the presence of p97 i
percentiles are shown as individual data points; n = 3 independent experiments;
(I) Representative images of the number RAD50 foci at 4 h of recovery after 2 Gy
(J) Quantifications of RAD50 foci as in (H). Data are presented as boxplot, and va
n = 3 independent experiments; Mann-Whitney test. NS, not significant; ****p < 0
(K) Effect of CB-5083 (10 mM) on MRN complex stability on chromatin fraction a
(L) Quantifications of normalized MRE11 levels on chromatin.
(M) Effect of CB-5083 (10 mM) on MRN complex stability in the soluble fraction (
(N) Quantifications of (M); n = 2.
See also Figures S1 and S2.Yeung et al., 2008; Meyer and Weihl, 2014). However, little is
known about how p97 regulates its substrates on chromatin dur-
ing DNA damage repair (Meyer et al., 2012; van den Boom and
Meyer, 2018; Singh et al., 2019; Meerang et al., 2011). In order
to identify relevant p97 substrates on chromatin after DNA dam-
age from IR, we designed a triplex stable isotope labeling with
amino acids in cell culture (SILAC) mass spectrometry experi-
ment (Figures 1A and 1B) using a stable transfected and doxycy-
cline (DOX) inducible dominant-negative p97-E578Q (EQ) variant
in Human Embryonic Kidney 293 (HEK293) cells. This variant is
deficient in ATP hydrolysis but has the ability to bind ubiquiti-
nated substrates, thus serving as a substrate-trapping mutant
(Ye et al., 2003; Meerang et al., 2011; Ritz et al., 2011).
HEK293 cells were irradiated with 10 Gy IR, recovered over 8
h, p97 was isolated and analyzed by mass spectrometry for
p97 interaction partners relevant to DNA damage repair. An
increased interaction between p97 and the MRN complex
component RAD50 was observed on chromatin and in the nu-
cleus during 8 h of recovery after IR (Figure 1B).
Furthermore, we performed a reciprocal mass spectrometry
screen of the MRE11 interactome in T24 urinary bladder cancer
cells, which identified p97 as one of the top interaction partners
of MRE11, supporting our SILAC mass spectrometry findings.
The number of p97 peptides in the complex with MRE11 was
similar to the number of peptides of RAD50 and NBS1, the two
constitutive partners of MRE11 in the MRN complex (Figure 1C;
Table S1). Both mass spectrometry findings were confirmed by
co-immunoprecipitation of Strep-tag p97 or hemagglutinin
(HA)-MRE11 from chromatin extracts in HEK293 or T24 cells,
respectively, before and after IR (Figures 1D and 1E). The phys-
ical interaction between p97 and the MRN complex was also
corroborated between endogenous proteins (Figure 1F).
We hypothesized that p97 is involved in the regulation of the
MRN complex on chromatin, specifically by being required for
the disassembly of MRN from the chromatin. To test our hypoth-
esis, we quantified MRE11 and RAD50 nuclear foci after IR in
p97-inhibited conditions to determine whether MRN complex
components accumulate on sites of DNA damage. Treatmentamage
fter 10 Gy ionizing radiation (IR).
nd RAD50 interaction on chromatin after 10 Gy IR.
S1, and p97 peptides in similar abundance by MASCOT score.
raction of T24 cells. HA-tagged MRE11 was pulled down in the presence or
osed to IR (10 Gy) or not and fractionated to isolate the chromatin fraction and
(IgG) antibodies in HEK2923 cells showing p97 andMRN complex interactions
2 Gy IR and CB-5083 treatment (scale bars, 5 mm).
nhibitor (G). Data are presented as boxplot, and values beyond the 5th and 95th
Mann-Whitney test. NS, not significant; ***p < 0.001; ****p < 0.0001.
IR and CB-5083 treatment (scale bars, 5 mm).
lues beyond the 5th and 95th percentiles are shown as individual data points;
.0001.
fter IR in CHX-exposed T24 cells; n = 2 independent experiments.
cytoplasm and nucleus pooled; after IR) in CHX-exposed T24 cells.
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OPEN ACCESSwith CB-5083, a specific small-molecule inhibitor of p97, re-
sulted in an accumulation of both MRE11 and RAD50 (Figures
1G–1J) foci over 8 h after IR. However, the total protein levels
of the MRN complex components between CB-5083- and con-
trol-treated cells remained similar (Figures S1A and S1B), sug-
gesting that this accumulation is DNA and chromatin specific, re-
sulting from an accumulation of the available pool of RAD50 and
MRE11 that is not efficiently removed in the absence of p97.
Indeed, biochemical analysis of the MRN complex turnover by
cycloheximide (CHX) chase in soluble and chromatin fractions
after IR showed that chemical inhibition of p97 specifically
blocks the disassembly of the MRN complex from chromatin
but does not affect the overall turnover of the complex (Figures
1K–1N and S1E) in T24 cells. These results were more pro-
nounced in small interfering RNA (siRNA) p97-depleted T24 (Fig-
ures S1C and S1D) or HeLa cells (Figure S1F), suggesting a uni-
versal mechanism of MRN chromatin disassembly by p97. In
addition, the inactivation of p97 ATPase activity by a mild
expression of DOX-inducible p97-EQ variant also caused accu-
mulation of the MRN complex on chromatin, but not in the solu-
ble pool (Figures S1G–S1I).
To further support these results, we used UV-A laser microir-
radiation, which creates localized DNA damage in living cells
(Figure S2). Similar to our biochemical analysis, inactivation of
the p97 ATPase activity caused elevated accumulation of
MRE11 (Figures S2A and S2B) and RAD50 (Figures S2C and
S2D) at the sites of DNA lesions. Together, these data show
that p97 physically interacts with and removes theMRN complex
from chromatin and sites of DNA damage.
p97 inhibition results in excessive 50-DNA end resection
mediated by MRE11
We further sought to determine whether chromatin accumulation
of the MRN complex in p97-inactivated cells alters 50-DNA end
resection induced by MRE11 nuclease activity. For this, we
monitored ssDNA formation by bromodeoxyuridine (BrdU) assay
under native conditions. This assay allows visualization of ssDNA
by BrdU antibodies in immunofluorescence microscopy (Caron
et al., 2019). T24 cells were pretreated with BrdU for 24 h; briefly
labeled with 5’-ethynyl-2’-deoxyuridine (EdU), which served as a
marker for S-phase cells (EdU-positive cells); and then irradiated
or not (Figure 2A). Inactivation of p97 by CB-5083 or siRNA led to
increased DNA end resection (ssDNA; BrdU positive) in S-phase
(EdU-positive) cells (Figures 2B–2E, S3A, S3B, and S3E), which
was reversed upon treatment with the MRE11 inhibitor mirin or
by siRNA depletion of MRE11. Cells outside S phase were also
investigated, as previous studies have identified that MRE11Figure 2. p97 inhibition results in excessive DNA end resection mediat
(A) Schematic of the BrdU assay.
(B and C) Representative images (B) and quantification of EdU-positive BrdU foc
(D and E) Representative images (D) and quantification (E) of BrdU foci in EdU-po
(F and G) Representative images (F) and quantification (G) of EdU-negative BrdU
(H and I) Representative images (H) and quantification (I) of EdU-positive RPA70 fo
n = 3.
(J and K) Representative images (J) and quantification (K) of phosphorylated RPA
For all graphs, data are presented as boxplot, and values beyond the 5th and 95t
(E), and (G), Kruskal-Wallis with Dunn’s multiple comparisons was used. For (
****p < 0.0001. See also Figures S3 and S4.also functions in alt-NHEJ in G1 (Biehs et al., 2017). Both treat-
ment with CB-5083 and p97 depletion also caused BrdU foci
accumulation outside of S phase (EdU-negative cells; Figures
2F, 2G, and S3C–S3E), which was abrogated in combination
with mirin or siRNA-mediated MRE11 depletion. As expected,
no BrdU foci formed outside S phase in hydroxyurea (HU)-
treated cells, which were used as a positive control of
S-phase-dependent DNA end resection. The rescue phenotype
due to MRE11 inactivation was also confirmed with two addi-
tional MRE11 inhibitors against exonuclease and endonuclease
activity, indicating that this is not due to off-target effects of mirin
treatment (Figures S4A–S4D). Similar results were obtained
when formation of ssDNA (DNA end resection) was analyzed
by Replication Protein A (RPA), the major eukaryotic ssDNA-
binding protein (Figures 2H and 2I).
A recent report demonstrated that phosphorylated RPA nega-
tively regulates Bloom syndrome helicase and DNA end resec-
tion by establishing a negative feedback loop between resection
and its termination (Soniat et al., 2019). Therefore, RPA phos-
phorylation is inhibited in conditions where DNA end resection
is hyperactive. To this end, we investigated phosphorylated
RPA status in the context of p97 inhibition over 8 h of recovery
from IR. We hypothesized that phosphorylated RPA would not
accumulate to the same extent as total RPA when DNA end
resection is hyperactive. We were able to demonstrate that un-
like total RPA (Figures 2H and 2I), fewer serine 4/8 phosphory-
lated RPA foci were formed in CB-5083-treated conditions after
IR than in DMSO-treated cells (Figures 2J and 2K), further sup-
porting our findings that inactivation of p97 causes DNA hyper-
resection.
p97 inhibition delays DSB repair and causes a switch
from ‘‘error-free’’ RAD51-mediated repair to mutagenic
repair by RAD52
When ssDNA levels exceed a certain threshold, HR repair is
compromised, and cells are more likely to be repaired by an
alternative mutagenic end-joining pathway such as SSA
(Duursma et al., 2013). Additionally, compromised 53BP1
recruitment has been shown to cause a switch from error-free
gene conversion mediated by RAD51 to RAD52-mediated SSA
(Ochs et al., 2016; Jiang et al., 2021). One of the mechanisms
by which this occurs is through the release of an inhibitory brake
on RAD52 by RAD51 (Ceccaldi et al., 2016). To understand the
molecular consequences of increased ssDNA formation after
CB-5083 treatment on DNA repair pathway choice, we studied
the kinetics of RAD51 (Figures 3A and 3B) and RAD52 (Figures
3C and 3D) foci after 2 Gy IR and observed that p97 inhibitioned by MRE11
i (C) in CB-5083- and mirin-treated T24 cells. Scale bars, 5 mm; n = 3.
sitive T24 cells after 2 Gy IR and 1 or 4 h of recovery. Scale bars, 5 mm; n = 3.
foci in CB-5083- and mirin-treated T24 cells. Scale bars, 5 mm; n = 3
ci at 4 h of recovery after 2 Gy IR in CB-5083 treated T24 cells. Scale bars, 5 mm;
foci (S4/S8) formation at 1 h of recovery from 2 Gy IR. Scale bars, 5 mm; n = 3.
h percentiles are shown as individual data points. For statistical analysis in (C),
I) and (K), the Mann-Whitney test was used. NS, not significant; **p < 0.01;
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Figure 3. p97 inhibition results in a change from error-free homologous recombination (HR) to mutagenic repair by RAD52
(A and B) Representative images (A) and quantification (B) of the number of RAD51 foci of EdU-positive T24 cells at 4 h after 2 Gy IR andCB-5083 treatment. Scale
bars, 5 mm; n = 3.
(C andD) Representative images (C) and quantification (D) of the number of RAD52 foci of EdU-positive T24 cells at 4 h after 2Gy IR andCB-5083 treatment. Scale
bars, 5 mm; n = 3.
(E) U2OSDR-GFP cells were either transfected with indicated siRNAs for 48 h or treatedwith 10 mMCB-5083 for 6 h. Cells were transfectedwith I-SceI plasmid for
at least 8 h to induce DNA breaks, and HR repair was monitored by fluorescence-activated cell sorting (FACS).
(F) U2OSDR-GFP cells were transfected with I-SceI plasmid as in (E) and treatedwith p97 siRNA (10 nMover 48 h); n = 3; one-way ANOVAwith Dunnett’s multiple
comparisons. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (E and F).
(G) Western blot showing RAD51 and p97 knockdown efficiencies.
(legend continued on next page)






OPEN ACCESSdecreases RAD51 foci formation and increases RAD52 foci. To
measure DSB repair quantitatively, we used direct-repeat
(DR) HR and SSA green fluorescent protein (GFP)-based re-
porters integrated into U2OS cells, where DSBs are induced
by expressing I-SceI nuclease. Inactivation of p97 by either
CB-5083 treatment or siRNA depletion caused a reduction in
HR-repair efficiency compared to the I-SceI-treated positive
control (Figures 3E–3G), indicating that p97 is required for effi-
cient HR repair as previously shown (Meerang et al., 2011; van
den Boom et al., 2016). Furthermore, inhibition of p97 increased
SSA repair capacity by 30% when compared to I-SceI-treated
control cells. This indicates that SSA repair is effectively taking
place in a background of major HR deficiency (Figures 3H and
3I). Inactivation of RAD51 or RAD52 by siRNAwas used as a pos-
itive control for defective HR and SSA repair, respectively.
Inactivation of p97 leads to compromised HR activity due to
uncontrolled MRE11-dependent DNA end resection. We there-
fore hypothesized that chemical inhibition of p97 by CB-5083
treatment or siRNA depletion in combination with IR would result
in sustained DNA damage and therefore lead to unrepaired
DSBs, thus resulting in radiosensitization, which might be
exploitable clinically. We quantified 53BP1 and g-H2AX nuclear
foci after 2 Gy IR and monitored repair over 24 h (Figures 4A–4C,
4F, and S5A–S5C). In addition to being a marker of DSB repair
efficiency, 53BP1 counteracts DNA end resection by limiting
the access of HR factors and nucleases to DNA ends (Ghezraoui
et al., 2018). In line with our hypothesis, there was a significant
impairment of 53BP1 recruitment in p97-depleted or CB-5083-
treated cells until 4 h; however, DNA damage repair was delayed
when quantified by the number of g-H2AX foci over 24 h. Addi-
tionally, we questioned whether there is a recruitment defect in
other anti-resection factors upon p97 depletion. Specifically,
we studied the recruitment of the Shieldin complex component
REV7 that is in an effector complex with 53BP1. Depletion of
p97 resulted in defective REV7 recruitment to sites of IR-induced
damage until 4 h post-IR (Figures 4D–4F), demonstrating similar
kinetics to 53BP1. Interestingly, despite defective initial recruit-
ment to the sites of IR-foci in p97-inactivated cells at early time
points (over 4 h post-IR), both anti-resection factors (53BP1
and REV7) were more persistent at 24 h post-IR in p97-inacti-
vated cells when compared to control cells. This suggests that
DNA damage in p97-inactivated cells persists at 24 h after IR,
and some of these damage sites are marked with 53BP1 and
REV7. Our conclusion is in accordance with the persistence of
g-H2AX (Figures 4A, 4C, S5A, and S5B) and increased cell sensi-
tivity to IR in p97-inactivated cells (see later in Figure 7).
To understandwhether the 53BP1 recruitment defect observed
in p97 inactivated cells is a direct result of MRE11 regulation or an
indirect effect, we studied 53BP1 recruitment to sites of IR-
induced DNA damage in both KU80- and Lethal(3)malignant brain
tumor-like protein 1 (L3MBTL1)-depleted conditions. KU80 and(H) U2OS SA-GFP cells were treated as in (E); however, siRAD52 was used inste
repair. The I-SceI group serves as a positive control that is normalized to 100%. O
n = 4 replicates.
(I) Western blot showing knockdown of RAD52.
Data in (B) and (D) are presented as boxplot with interquartile range shown, and v
The Mann-Whitney test was used for statistical analysis. NS, not significant; ****pL3MBTL1 are known p97 substrates upstream of 53BP1 and
REV7, affecting DSB repair pathway choice (van den Boom
et al., 2016; Acs et al., 2011). p97-dependent removal of KU80 di-
rects the DSB repair pathway from NHEJ to HR by facilitating
long-range DNA end resection, and p97-dependent removal of
L3MBTL1 facilitates the recruitment of 53BP1 to methylated his-
tone H4 in the vicinity of DNA damage. Depletion of KU80 did
not rescue the 53BP1 recruitment defect in p97-depeleted cells
(Figures 5A–5C), indicating that p97 regulates 53BP1 indepen-
dently of the KU70/80 heterodimer. Additionally, we observed
only a partial rescue of 53BP1 foci recruitment in p97-depleted
cells when L3MBTL1 was co-depleted (Figures 5D–5F, S6A,
and S6B), indicating that L3MBTL1 is not the sole p97 substrate
involved in controlling 53BP1 recruitment to sites of DSBs. This
suggests that other p97 substrates upstreamof 53BP1most likely
influence 53BP1 recruitment to IR-induced foci. We also
confirmed that p97 controls MRE11 chromatin accumulation
independently of KU70/80, as increased accumulation of
MRE11 at sites of DNA damage/IR-induced foci in p97-depleted
cells was not abolished by KU80 co-depletion (Figures 5G–5I).
We next sought to understand whether a defect in 53BP1
recruitment to sites of DNA damage in p97-inactivated cells
could be rescued by inactivation of the MRE11 nuclease activity.
To do so, T24 cells were treated with mirin, and the recruitment
of 53BP1 to the sites of IR-induced foci/DNA damage was moni-
tored. Interestingly, mirin-treated cells were able to fully rescue
defective 53BP1 recruitment in p97-depleted cells (Figures 5J
and 5K), indicating that theMRE11 nuclease activity poses a bar-
rier to 53BP1 recruitment when p97 is inactivated. Additionally,
there was no additive effect on 53BP1 recruitment in p97-
depleted cells when L3MBTL1 was co-depleted in combination
with mirin (Figures S6C and S6D). Overall, these results demon-
strate that p97 regulates MRE11 independently of the KU70/80
complex but also 53BP1 recuitment by preventing excessive
MRE11-dependent end resection.
p97 is more highly expressed in invasive than papillary
bladder cancer
Previous studies have shown p97 overexpression in several tu-
mors (Tsujimoto et al., 2004; Yamamoto et al., 2004a, 2004b,
2004c) and its association with metastasis and poor prognosis
in cancer patients (Tsujimoto et al., 2004). Using The Cancer
Genome Atlas (TCGA) data (Tang et al., 2019), we found statisti-
cally significantly higher p97 gene expression in breast, colon,
and prostate cancer compared to equivalent normal tissues (Fig-
ure 6A). p97 gene expression levels were also significantly higher
in muscle invasive bladder cancer (tumors N = 404) compared to
only 28 normal tissue samples. In the bladder cancer cases, high
tumor p97 expression levels were significantly correlated with
poorer disease-specific survival following bladder removal by
cystectomy (Figure 6B).ad of siRAD51 as an internal control, and GFP positivity is a readout for SSA
ne-way ANOVA with Dunnett’s multiple comparisons: *p < 0.05; ****p < 0.0001;
alues beyond the 5th and 95th percentiles are shown as individual data points.
< 0.0001.
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OPEN ACCESSUsing immunohistochemistry, we compared cytoplasmic and
nuclear protein expression of p97 in papillary and invasive tumor
areas by H-score in 27 patient samples with high-grade non-
muscle invasive bladder cancer (NMIBC) with invasion to the
lamina propria (HGT1 stage). Strong cytoplasmic and nuclear
p97 staining was observed in invasive compared to papillary
areas (Figures 6C and 6D), suggesting that pathological progres-
sion of bladder cancer results in cells becomingmore dependent
on p97 function for survival.
CB-5083 acts as a radiosensitizer in bladder cancer
Inhibition of p97 has been found to induce apoptosis and reduce
overall cell survival in several cancer cell lines and mouse solid
tumor models (Anderson et al., 2015; Zhou et al., 2015; Le
Moigne et al., 2017; Auner et al., 2013). Furthermore, p97 deple-
tion has been found to sensitize U2OS cells to IR (Meerang et al.,
2011). We investigated p97 as a target for radiosensitization us-
ing T24 and RT112 bladder cancer cell lines in a clonogenic
assay, in the presence or absence of CB-5083, at inhibitory con-
centration (IC)10 and IC50 doses delivered 6 h prior to IR (Figures
7A–7C, S7A, and S7B). CB-5083-treated cells achieved signifi-
cant radiosensitization compared to control cells, as shown by
reduced clonogenic survival (Figures 7B and 7C). Supportive of
our molecular findings in vitro, where MRE11 nuclease inhibition
by mirin completely rescued the p97 inhibition phenotype, we
found in clonogenic assays that mirin treatment rescued radio-
sensitization caused by CB-5083 (Figures 7D and S7C). To
further support this finding, we confirmed the aforementioned
rescue phenotype by depleting p97 in RT112 cells with a stable
small hairpin RNA (shRNA) knockdown of MRE11 (shMRE11;
Figure 7E). As predicted, either siRNA-mediated p97 depletion
or shRNA MRE11 knockdown resulted in IR hypersensitivity of
RT112 cells (Singh et al., 2019; Meerang et al., 2011; Xu et al.,
2004; Yamaguchi-Iwai et al., 1999; Na et al., 2021; Stracker
and Petrini, 2011). Importantly, co-depletion of p97 and
MRE11 by siRNA and shRNA, respectively, completely rescued
IR sensitivity of RT112 cells. We conclude this rescue effect is
due to suppression of excessive MRE11-dependent DNA end
resection in p97-inactivated cells (Figures 2A–2G, S3, and S4)
and consequent restoration of 53BP1 foci (Figures 5J–5K) that
promote efficient NHEJ repair, the main pathway for cell survival
upon IR-induced DNA damage. Altogether, our results suggest
that one of the main roles of p97 in DDR and cell survival upon
IR is the regulation of MRE11 protein level on sites of DNA dam-
age and consequently its nuclease activity.
An alternative treatment to bladder removal by cystectomy in
muscle-invasive bladder cancer (MIBC) is bladder preservation,
based on treatment with radiotherapy (Kiltie, 2014; Alfred WitjesFigure 4. p97 inhibition and depletion negatively regulate the anti-rese
break (DSB) repair
(A–C) Representative images (A) and quantification of 53BP1 (B) and gH2AX (C) fo
n = 3; Mann-Whitney test. NS, not significant; ****p < 0.0001.
(D and E) Representative images (D) and quantification of REV7 (E) foci kinetics
presented as boxplot with interquartile ranges shown, and values beyond the 5th
not significant; ****p < 0.0001.
(F) Western blot demonstrating the efficiency of siRNA p97 knockdown.
See also Figure S5.et al., 2017). As many currently used radiosensitizing agents add
to the toxicity of radiotherapy, new approaches are required.
Proteotoxic stress is a secondary hallmark of cancer (Guang
et al., 2019), because cancer cells accumulate defective proteins
at a significantly higher rate compared to normal cells, which
makes cancer cells more dependent on the proteasome for their
removal (Adams, 2004). Therefore, the use of CB-5083 may
spare normal tissues.
CB-5083 has been studied as a single agent in vivo, but not in
combination with IR. Having established CB-5083 as a radiosen-
sitizer in bladder cancer cell lines, we used a bladder cancer su-
perficial flank xenograft model to determine whether inhibiting
p97 would sensitize tumors to IR. CD-1 nude mice bearing
RT112 xenografts were treated with a single dose of CB-5083 at
25 mg/kg via intraperitoneal injection, and plasma, liver, kidney,
bladder, and tumor concentrations of CB-5083 were analyzed
6 h after treatment to determineCB-5083 uptake in various organs
and in tumors (Figure 7F). Uptake was significantly higher in tu-
mors (mean, 25 mM) than the CB-5083 plasma concentration
(mean, 5 mM). Additionally, CB-5083 uptake was significantly
higher in the organs analyzed compared to plasma. The drug
was well tolerated at these doses, with no significant body weight
loss over the course of a week in CD-1 nude mice given a single
intraperitoneal dose of CB-5083 at 25 mg/kg (n = 2) or 50 mg/kg
(Figure S7D).
Mice with RT112 xenograft tumors treated with a single 25-mg/
kg intraperitoneal injection of CB-5083 6 h prior to radiotherapy (6
Gy, single fraction) showed significant tumor growth inhibition at
day 8 compared to control, IR-only, or drug-only groups (Fig-
ure 7G). Although the time to reach 50 mm3 in size for the start
of the treatment was not significantly different between groups
(Figure S7E), the time to treble tumor volume was significantly
longer in the combined group than in the control group, but not
in the IR-only and CB-5083-only groups (Figure S7F).
We then studied the effects of an intraperitoneal injection of
25 mg/kg CB-5083 on acute intestinal toxicity from IR in CD-1
nude mice using an intestinal crypt assay as previously
described (Groselj et al., 2018). The vehicle- and CB-5083-alone
groups demonstrated no overall crypt loss, andCB-5083 in com-
bination with 10, 12, or 14 Gy radiation demonstrated no further
loss of crypts compared to radiation alone (Figures 7H and S7G).
Altogether, these in vivo results suggest that a single dose of the
p97 inhibitor CB-5083 at 25 mg/kg reduces the growth of
bladder cancer xenografts treated with IR, with no exacerbation
of acute normal tissue toxicity to the surrounding small intestine
of CD-1 nude mice under the observed conditions. These in vivo
data support our biochemical and cell biological data obtained
in vitro.ction factors 53BP1 and REV7, causing a delay in DNA double-strand
ci kinetics over 24 h in p97-depleted T24 cells after 2 Gy IR. Scale bars, 5 mm;
in p97-depleted T24 cells over 24 h after 2 Gy IR. Scale bars, 5 mm. Data are
and 95th percentiles shown as individual points; n = 3; Mann-Whitney test. NS,
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We demonstrate that MRE11 accumulation on DNA damage and
chromatin is regulated by the ubiquitin-dependent ATPase p97
and show that inhibiting p97 activity leads to uncontrolled
MRE11 nuclease activity on chromatin. However, maintaining
balanced levels of MRE11 on chromatin is necessary for genomic
stability. We postulate that disrupting this balance by inactivating
p97 could be one of themechanisms bywhich cancer cells are ra-
diosensitized and are therefore more likely to undergo cell death.
We propose this occurs because excessive accumulation of
MRE11 on chromatin leads to pathological 50-DNA end resection
and inhibition of the error-free HR pathway. Our model (Figure 7I)
has potential implications for cancer therapy.
p97 is a molecular segregase involved in the timely removal of
DDR factors to maintain genomic stability. Among its known
substrates at sites of DNA damage are key DNA repair factors
such as the KU complex, RNF8, and RAD51 (Singh et al.,
2019; Torrecilla et al., 2017). Our mass spectrometry data,
confirmed by chromatin immunoprecipitation, identified that
theMRN complex is one of themost prominent complexes asso-
ciated with p97, where the number of p97 peptides in complex
with MRE11 was similar to the number of the two MRE11 consti-
tutive binding partners RAD50 and NBS1. This indicates that p97
might be one of the essential factors for the function of the MRN
complex and thus important for controlling MRE11 nuclease ac-
tivity. To address the functional relevance of the interaction be-
tween p97 and the MRN complex, we demonstrate that p97
inactivation blocks the disassembly of the MRN complex from
chromatin, especially its catalytic subunit, MRE11, but does
not affect the overall turnover of the MRN complex. This has
important implications for DNA repair and cell survival.
Homeostasis of the nuclease MRE11 is necessary in the main-
tenance of genomic stability, as insufficient MRE11 nuclease
activity compromises error-free HR repair (Jachimowicz et al.,
2019; Buis et al., 2008). Furthermore, its over-accumulation
leads to excessive DNA end resection that results in pathological
DNA repair, degradation of nascent DNA strands, and genome
instability syndromes (Hashimoto et al., 2010; Ray Chaudhuri
et al., 2016; Schlacher et al., 2011). Previously, it has been shown
that UBQLN4 removes ubiquitinated MRE11 from chromatin to
favor NHEJ (Jachimowicz et al., 2019), DYNLL1 interacts with
MRE11 directly to limit its nuclease activity in BRCA1-deficient
cells (He et al., 2018), and C1QBP binds directly to MRE11 to
maintain the MRE11/RAD50 protein pool while limiting MRE11
exonuclease activity (Bai et al., 2019). Furthermore, ataxia telan-
giectasia mutated (ATM)-dependent phosphorylation of MRE11Figure 5. p97 regulates 53BP1 foci formation and accumulation of MR
(A and B) Representative images (A) and quantification (B) of the number of 53B
(C) Western blot showing knockdown of p97 and KU80.
(D and E) Representative images (D) and quantification (E) of the number of 53B
(F) Western blot showing knockdown of p97 and L3MBTL1.
(G and H) Representative images (G) and quantification (H) of the number of MR
(I) Western blot showing knockdown of p97 and KU80.
(J and K) Representative images (J) and quantification (K) of the number 53BP1
Data in (B), (E), (H), and (K) are presented as boxplot with interquartile ranges sho
and analyzed by Mann-Whitney test (B, E, and H) or Kruskal-Wallis test with Dunn
bars, 5 mm; n = 3. See also Figure S6.at S676/678 leads to its removal from chromatin, and phospho-
defective mutations of these two serines cause MRE11 retention
on chromatin, excessive DNA end resection, and decreased HR
but a functional SSA repair pathway (Kijas et al., 2015). However,
how exactly MRE11 is disassembled from the sites of DNA dam-
age is poorly understood.
Here, wedemonstrate that the ATPase activity of p97 physically
disassembles MRE11 from the sites of DNA damage. Thus, p97
inactivation has functional relevance for MRE11 nuclease activity
by causing excessive ssDNA formation. It has been previously
shown that when DSBs accumulate ssDNA above physiological
levels, HR is compromised and cells are more likely to be repaired
by an alternative and mutagenic SSA pathway (Duursma et al.,
2013). For example, it is known that upon compromising 53BP1
foci formation, DNA repair template switch occurs from RAD51-
mediated HR to RAD52-mediated SSA (Ochs et al., 2016). This
has pathological consequences for the cell, as it leads to a change
from error-free repair to mutagenic repair, causing deletion rear-
rangements within the genome (Bhargava et al., 2016). In line
with previous literature, we also demonstrate that inactivating
p97 leads to reduced Rad51 foci formation after IR and a template
switch from RAD51-mediated HR to SSA mediated by RAD52.
The reason for the switch from RAD51 to RAD52 occurs because
of their antagonistic relationship, and upon disruption of RAD51
function, an inhibitory brake on RAD52 is released (Ceccaldi
et al., 2016). Furthermore, decreased recruitment of the anti-
resection factors 53BP1 and REV7 to the sites of IR-induced
foci in p97-inactivated cells forms a permissive environment for
DNA end resection, which is in agreement with our observations.
It has been shown that p97-dependent disassembly of the
KU70/80 heterodimer from DSB ends is essential for DSB repair
and regulation of HR-repair pathway (van den Boom et al., 2016).
Specifically, inactivation of the p97-Ufd1-Npl4 complex causes
retention of the KU70/80 heterodimer, which stimulates NHEJ
repair but blocks the HR-repair pathway. This might suggest
that the here-discovered regulation of MRE11 by p97 is an indi-
rect process over KU70/80. However, we demonstrated that
regulation of MRE11 by p97 is a direct process, as p97 physically
forms a complex with the MRN complex, and MRE11 retention
on sites of DNA damage in p97-inactivated cells is KU70/80 in-
dependent. Also, the 53BP1 recruitment defect seen in p97-in-
activated cells could not be restored by KU80 depletion, which
causes degradation of the entire KU70/80 complex (van den
Boom et al., 2016; Nussenzweig et al., 1996; Fink et al., 2010).
Conversely, the 53BP1 foci recruitment defect in p97-inactivated
cells could be completely or partially restored by inactivation of
MRE11 by mirin or depletion of L3MBTL1, respectively. The fullE11 on sites of DNA damage independently of KU70/80
P1 foci at 1 h after recovery from 2 Gy IR in T24 cells.
P1 foci at 1 h after recovery from 2 Gy IR in T24 cells.
E11 foci 1 h after recovery from 2 Gy IR in T24 cells.
foci at 1 h after recovery from 2 Gy IR in T24 cells.
wn, and values beyond the 5th and 95th percentiles shown as individual points
’s multiple comparisons (K). NS, not significant; *p < 0.05; ****p < 0.0001. Scale
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Figure 6. Gene and protein expression levels of p97 in urothelial carcinoma
(A) TCGA p97 gene expression levels across different cancer types, comparing tumor expression levels (shown as red dots) to normal tissue (shown as green
dots). Bladder cancer is abbreviated ‘‘BLCA.’’ Tumor abbreviations in red have a statistically significant increase in p97 gene expression compared to normal
tissues, whereas abbreviations in green have higher levels of p97 gene expression in normal tissues. Abbreviations in black show no statistically significant effect.
(B) Disease-specific survival analysis of p97 gene expression; log-rank test, *p = 0.05.
(C) Representative images of two tumor cases from a total of 27 patients with urothelial carcinoma stained with p97 antibody. Each vertical tile represents a
separate case (marked as ‘‘I’’ and ‘‘II’’). The invasive and papillary areas show the highest and the lowest nuclear staining intensity, respectively.
(D) Cytoplasmic and nuclear p97 H-scores in papillary and invasive regions are shown. Data are presented as mean H-score ± SEM. Mann-Whitney U test:
**p < 0.01 and ****p < 0.0001.




Figure 7. CB-5083 radiosensitizing effects and acute normal tissue toxicity
(A) Chemical structure of CB-5083.
(B and C) Linear quadratic survival curves of T24 (B) and RT112 (C) cells treated with IR either in combination with CB-5083 IC10 (T24, 1 mM; RT112, 1 mM) and
IC50 (T24, 6 mM; RT112, 10 mM), or alone. Statistical significance is indicated on the respective graphs, where the upper row represents IC10 in comparison to the
(legend continued on next page)






OPEN ACCESSrestoration of 53BP1 IR foci in p97-inactivated cells by MRE11
inactivation, either by chemical inhibition (mirin) or by siRNA-
mediated MRE11 depletion, in two different cell lines indicates
that MRE11 accumulation acts as a barrier to 53BP1 recruitment
in p97-inactivated conditions. Altogether, our findings demon-
strate that the physical and functional relationship between
p97 and MRE11 is a separate process from the previously
described p97-KU70/80 axis in the regulation of DSB pathway
choice.
After understanding the molecular aspects of p97 inactivation,
we demonstrated the potential clinical benefits of p97 inhibition
in combination with radiotherapy. When cancer cells become
dependent on the UPS for survival, it is expected that targeting
specific agents within the UPSwill lead to cancer cell death while
having minimal effects on normal cells, as there is no proteotoxic
stress under normal conditions (Adams, 2004). By combined tar-
geting of proteostasis and the DDR, we validated the usefulness
of combined p97 inhibitor/radiotherapy using clonogenic assays
and a mouse xenograft model. With no increase in acute radia-
tion toxicity following addition of CB-5083 at a dose that
achieved tumor radiosensitization, targeting proteotoxic stress
may be a promising clinical target. Furthermore, by assessing
p97 expression in NMIBC (HGT1) patient samples, we demon-
strate that both cytoplasmic and nuclear p97 expression levels
are significantly higher inmore invasive areas compared to papil-
lary areas. This is in agreement with previous literature showing
that overexpression of p97 occurs in a variety of tumor types
(Tsujimoto et al., 2004; Yamamoto et al., 2004a, 2004b,
2004c), and this overexpression exemplifies the need for the
UPS in cancer cells as a survival mechanism. Additionally, we
validated these results using the TCGA database on p97 gene
expression levels in various tumors compared to normal tissues.
All of the above observations support the notion that cancer cells
rely on the function of p97 for survival.
In summary, we have shown that by controlling the timely
removal of MRE11 from chromatin, p97 regulates the extent
and balance of DNA end resection after DNA damage. By in-
activating p97, we show that MRE11 accumulates on chro-
matin, which leads to ssDNA buildup in cells. The MRE11-
mediated excessive end resection decreases HR efficiencycontrol, and the second row represents IC50 in comparison to the control. NS, not
See also Figure S2.
(D) Survival of T24 cells after IR and treatment with CB-5083, mirin, or both; n = 2
way ANOVA, comparing CB-5083 and CB-5083 + mirin. Statistical significance,
(E) Survival of RT112 cells with or without stable small hairpin RNA (shRNA)MRE11
treated with siRNA control or siRNA against p97. N = 3 individual biological experim
ANOVA, comparing RT112 + sip97 and RT112 shMRE11 + sip97 conditions. Stati
the experiment in (E).
(F) Plasma, bladder, kidney, liver, and tumor concentrations (in mM) of CB-5083 in t
treatment at 25 mg/kg (N = 5). Statistical analysis: *p < 0.05; **p < 0.01 (unpaired
(G) RT112 cells were subcutaneously injected into CD-1 nude mice to establish
25 mg/kg CB-5083 and radiotherapy (6 Gy, single fraction) in RT112 xenografts
parisons).
(H) Small crypt assay survival for CB-5083 and mock-treated C-1 nude mice over
IR. Data were normalized to mean crypts per millimeter in mock-treated and CB
(I) Model of the role of p97 in DSB repair pathway choice. Left: under physiologic
DSBs by the ATPase activity of p97 to promote HR-mediated repair. Right: inactiv
DSBs, leading to excessive 50-DNA end resection, subsequent HR defects, and
See also Figure S7.
14 Cell Reports 35, 109153, May 25, 2021and increases RAD52-dependent SSA. Consequently, this
leads to increased tumor cell killing following IR both in vitro
and in vivo. We propose this could be therapeutically ex-
ploited in further studies.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Antibodies
BrdU Mouse monoclonal BD Biosciences Cat# 347580; RRID:AB_10015219
Phospho-Histone H2A.X (Ser139) Mouse monoclonal Millipore Cat#05-636; RRID:AB_309864
Phospho-Histone H2A.X (Ser139) Rabbit polyclonal Cell Signaling Cat# 2577; RRID:AB_2118010
RPA70/RPA1 Rabbit polyclonal Cell Signaling Cat# 2267; RRID:AB_2180506
P97/VCP Rabbit polyclonal Proteintech Cat# 10736-1-AP; RRID:AB_2214635
53BP1 Rabbit polyclonal Cell Signaling Cat# 4937; RRID:AB_10694558
RAD51 Mouse monoclonal Santa Cruz Cat# 398587; RRID:AB_2756353
RAD52 Mouse monoclonal Santa Cruz Cat# 365341; RRID:AB_10851346
RAD50 Mouse monoclonal Abcam Cat# 89; RRID:AB_2176935
MRE11 Rabbit polyclonal Abcam Cat# 33125; RRID:AB_776530
MRE11 Mouse monoclonal Abcam Cat# ab214; RRID:AB_302859
L3MBTL1 Rabbit polyclonal Abcam Cat# ab51880; RRID:AB_873913
MAD2B Mouse monoclonal BD Biosciences Cat# 612266; RRID:AB_399583
NBS1 Mouse monoclonal BD Biosciences Cat# 611870; RRID:AB_399350
Vinculin Mouse monoclonal Abcam Cat# ab18058; RRID:AB_444215
Lamin A/C Mouse monoclonal Cell Signaling Cat# 4777; RRID:AB_10545756
Histone H2B Rabbit monoclonal Cell Signaling Cat# 12364; RRID:AB_2714167
Alexa Fluor 488 Rabbit polyclonal Thermo Fisher Scientific Cat# A-11034; RRID:AB_2576217
Alexa Fluor 488 Mouse polyclonal Thermo Fisher Scientific Cat# A-21202; RRID:AB_141607
Alexa Fluor 568 Rabbit polyclonal Thermo Fisher Scientific Cat# A-11011; RRID:AB_143157
Alexa Fluor 568 Mouse polyclonal Thermo Fisher Scientific Cat# A-10037; RRID:AB_2534013
RPA32/RPA2 (phospho S4+S8) rabbit polyclonal Abcam Cat# ab87277; RRID:AB_1952482
KU80 Mouse monoclonal Abcam Cat# 119935; RRID:AB_10899161
Lamin B1 Rabbit polyclonal Thermo Fisher Scientific Cat# PA5-19468; RRID:AB_10985414
Mouse 800 secondary LI-COR Cat# 925-32210; RRID:AB_2687825
Rabbit 680 secondary LI-COR Cat# 925-68021; RRID:AB_2713919
b-actin Mouse monoclonal Thermo Fisher Scientific Cat# AM4302; RRID:AB_437394
b-actin Rabbit (13E5) monoclonal Cell Signaling Cat# 4970; RRID:AB_2223172
Control Rabbit IgG Non-commercial Kristijan Ramadan Lab
Rabbit IgG (HRP conjugated) Goat polyclonal Sigma-Aldrich Cat# A9169; RRID:AB_258434
Mouse IgG (HRP conjugated) Rabbit polyclonal Sigma-Aldrich Cat# A9044; RRID:AB_258431
Biological samples
Bladder cancer human tumor samples (HGT1) Oxford Radcliffe Biobank http://orb.ndcls.ox.ac.uk
Chemicals, peptides, and recombinant proteins
BrdU Sigma-Aldrich Cat# B5002
EdU Thermo Fisher Scientific Cat# A10044
Cycloheximide Sigma-Aldrich Cat# C1988
Benzonase Millipore Cat# 71205
Doxycycline PanReac AppliChem Cat# A2951,0025
Hoechst 3325 Sigma-Aldrich Cat# 23491-45-4
RNase A (10 mg/mL) Thermo Fisher Scientific Cat# EN0531
ProLong Diamond antifade with DAPI Thermo Fisher Scientific Cat# P36962
(Continued on next page)
e1 Cell Reports 35, 109153, May 25, 2021
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail Roche Cat# 11836170001
Intercept (PBS) Blocking Buffer LI-COR Cat# 927-70001
Sequencing Grade Modified Trypsin Promega Cat# V5111
BSA Sigma-Aldrich Cat# 9048-46-8
Fisher Bioreagents Phosphatase Inhibitor Cocktail I Thermo Fisher Scientific Cat# 12821650
Pierce Protease Inhibitor Mini Tablets, EDTA-free Thermo Fisher Scientific Cat# A32955
Hoechst 33342 Thermo Fisher Scientific Cat# H3570
Lipofectamine RNAiMAX Thermo Fisher Scientific Cat# 13778-150
QIAGEN maxiprep kit QIAGEN Cat# 12362
FuGENE Transfection Reagent Promega Cat# E2311
jetPRIME Transfection Reagent Polyplus-transfection Cat# 114-01
Opti-MEM reduced serum medium Thermo Fisher Scientific Cat# 11058021
CB-5083 MedChem Express Cat# HY-12861
Mirin Sigma-Aldrich Cat# M9948
PFM01 Tocris Cat# 6222
PFM39 Sigma-Aldrich Cat# SML1839
DMSO Sigma-Aldrich Cat# D2650
Methyl cellulose Thermo Fisher Scientific Cat# 155496
NEM Sigma-Aldrich Cat# EE3876-25G
Tween-20 Sigma-Aldrich Cat# P7949
Tween-80 Sigma-Aldrich Cat# 9005-65-6
Puromycin GIBCO Cat# A11138-03
G-418 Sigma-Aldrich Cat# 108321-42-2
Gefitinib Sigma-Aldrich Cat# SML1657
Matrigel BD Biosciences Cat# 356237
PBS GIBCO Cat# 10010023
20X Transfer buffer Bio-Rad Cat# 10026938
10X Running buffer Bio-Rad Cat# 1610772
Laemmli 2X concentrate Sigma-Aldrich Cat# S3401
Antibody diluent LI-COR Cat# 927-75001
Hydroxyurea (HU) Sigma Cat# H8627
Triton X-100 Sigma-Aldrich Cat# T8787
HEPES Sigma-Aldrich Cat# H4034
Sucrose Sigma-Aldrich Cat# S0389
MgCl2 Thermo Fisher Scientific Cat# AM9530G
NaCl Sigma-Aldrich Cat# S5150
EDTA Thermo Fisher Scientific Cat# 15575020
Tris hydrochloride Sigma-Aldrich Cat# 1185-53-1
Formaldehyde 36% (39% w/v) VWR Cat# 50-00-0
Click-IT EdU Alexa Fluor 647 imaging kit Thermo Fisher Scientific Cat# C10340
Pierce Anti-HA Magnetic Beads Thermo Fisher Scientific Cat# 88836
Dynabeads Protein A Thermo Fisher Scientific Cat# 10002D
Portein A magnetic beads NEB Cat# S1425S
Dynabeads Protein G Thermo Fisher Scientific Cat# 10003D
Strep-Tactin Sepharose 50% suspension beads IBA Life Sciences Cat# 2-1201-010
MagStrep ‘‘type3’’ XT beads IBA Life Sciences Cat# 2-4090-002
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Deposited data
ProteomeXchange Consortium PRIDE PXD016279
Experimental models: cell lines
Human: T-24 German Collection of
Microorganisms
and Cell Cultures (DSMZ)
DSMZ No 376
Human: RT112 German Collection of
Microorganisms
and Cell Cultures (DSMZ)
DSMZ No 418
Human: HEK293 ATCC Cat# 300192/p777_HEK293
Human: HeLa ATCC Cat# CCL-2
Human: DR-GFP U2OS Laboratory of Dr Timothy
Humphrey (Ahrabi et al.,
2016)
N/A
Human: SA-GFP U2OS Laboratory of Dr. Pavel
Janscak (Paliwal et al.,
2014)
N/A
HEK293 Flp-In T-REx (p97-E578Q-cSSH) Laboratory of Prof Kristijan
Ramadan (Meerang et al.,
2011)
N/A
RT112 (shMRE11) Laboratory of Prof Anne E
Kiltie (Na et al., 2021)
N/A
Experimental models: organisms/strains
CD-1 nude mice (Female) Charles River Laboratories Strain Code:
086 (Homozygous)
Oligonucleotides
siRNA_Control (proprietary sequence) QIAGEN Cat# 1027280
siRNA_RAD51 (50- AAGGGAATTAGTGAAGCCAAA-30) QIAGEN Cat# SI02663682
siRNA_RAD52 (50-AAGGATGGTTCATATCATGAA-30) QIAGEN Cat# SI03035123
siRNA_MRE11 (50GAGCAUAACUCCAUAAGUA(dT)(dT)-30) Thermo Fisher Scientific Cat# 10620310
siRNA_XRCC5/siKU80 (50-GCAUGGAUGUGAUUCAACA-30) Dharmacon Cat# 7520
siRNA_VCP_7 (50-UUCUGUUUGAGAAUGGCUGUU-30) Thermo Fisher Scientific Cat# 10620310
siRNA_VCP_7 (50-AACAGCCAUUCUCAAACAGAA-30) QIAGEN N/A
siRNA_L3MBT1_5 (50-AAGCGAGUAUAAGCC-30) Microsynth N/A
siRNA_L3MBT1_7 (50-CCAGGCAGUCACUCA-30) Micorynth N/A
Recombinant DNA
pcDNA3.3 N-term HA-MRE11 Laboratory of Anne E Kiltie
(Nicholson et al., 2017)
N/A
pcDNA5-p97-EQ-Myc-Strep Laboratory of Hemmo Meyer
or Kristijan Ramadan
(Meerang et al., 2011)
N/A
Software and algorithms
Prism 8 GraphPad Software https://www.graphpad.com
Fiji NIH https://imagej.net/Fiji/Downloads
FlowJo v10 FlowJo https://www.flowjo.com/solutions/flowjo/
downloads
Image Studio Lite 5.2 LI-COR https://www.licor.com/bio/image-studio-
lite/download
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Proteome Discoverer Software Thermo Fisher Scientific https://thermo.flexnetoperations.com/
control/thmo/login
MASCOT 2.3 Matrix Science Inc http://www.matrixscience.com/







Kristijan Ramadan (kristijan.ramadan@oncology.ox.ac.uk) should be contacted for requests regarding resources, data and reagents
used in this study.
Materials availability
All reagents generated in this study are available from the lead contact or Anne E Kiltie, except human HGT1 tissue sections. The
Oxford Radcliffe Biobank (http://orb.ndcls.ox.ac.uk) should be contacted for HGT1 tissue sections.
Data and code availability
MRE1 -mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repos-
itory with the dataset identifier PXD016279.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All animal experiments were conducted in accordance with HomeOffice regulations for animal testing and research and approved by
the University of Oxford Animal Welfare and Ethical Review Body (AWERB) under University of Oxford project licenses PPL
P4B738A3B and P8484EDAE. CD-1 nude mice were obtained from Charles River Laboratories at the age of 7 weeks. All mice
usedwere female and the experiment startedwhen themicewere at the age of 8weeks.Micewereweighed before the start of exper-
iment and from there onward three times a week. Mice were kept up to 6 mice per cage and maintained in individually ventilated
cages (IVCs).
Human HGT1 tissue sections
High-grade non-muscle invasive bladder cancer human tumor samples (HGT1) were identified in the Oxford Radcliffe Biobank.
Twenty-seven cases obtained between the years 2009 to 2015 were used under the appropriate ethical approval (South Central Ox-
ford REC C 09/H0606/5+5). A total of eight patients underwent radical cystectomy. Muscle invasive disease was identified in the
resection specimen of one patient post-cystectomy (pT2). Two patients demonstrated disease progression following biopsy for dis-
ease recurrence in 2013 and 2015. Both patients included in Figures 6C and 6D (I and II) were males, and 59 and 69 years old,
respectively.
Cell lines
T24 and RT112 cell lines were obtained fromGerman Collection of Microorganisms and Cell Cultures (DSMZ). HeLa and HEK293 cell




T24 and HEK293 cells were grown in DMEMmedium, and RT112 cells were grown in RPMI-1640medium. DR-GFP U2OS cells were
provided by Dr. Sovan Sarkar, University of Oxford, and grown in DMEM medium supplemented with 3 mg/mL puromycin. SA-GFP
U2OS cells were provided by Dr. Pavel Janscak, University of Zurich, and grown in DMEM supplemented with 3 mg/mL puromycin.
Stable HEK293 Flp-In T-REx (p97-E578Q-cSSH) cells for p97 SILAC-MS were used as previously described (Meerang et al., 2011).
RT112 cells with stable shRNA knockdown of MRE11 were kept in RPMI-1640 medium supplemented with G418 (500 mg/mL), and
provided by Dr. Juri Na, University of Oxford. Cells were treated as follows: 10 mM BrdU (#B5002; Sigma) and 10 mM Edu (#C1042;
Sigma) for 24 hours and in the last 20 minutes of the 24 hours, respectively; 10 mM CB-5083 (#HY-12861; MCE) for 2 hours; 500 mM
hydroxyurea (#H8627; Sigma) for 1 hour; MRE11 inhibitors usedwere 100 mMMirin (#M9948; Sigma), 100 mMPFM01 (#6222; Tocris),Cell Reports 35, 109153, May 25, 2021 e4
Article
ll
OPEN ACCESS100 mM PFM39 (#SML1839; Sigma) for 3 hours. Concentrations of PFM01 and PFM39 were chosen according to a previous publi-
cation (Shibata et al., 2014). For clonogenic survival assays, appropriate concentrations of CB-5083 and Mirin were applied for
6 hours and 24 hours, respectively.
RNA interference
The siRNA sequences for control and indicated genes were transfected in cells using Lipofectamine RNAiMAX (Thermo Fisher Sci-
entific) according to the manufacturer’s protocol. Knockdown efficiency was assessed 24-48 hours post-transfection.
Xenograft model for tumor growth delay
All animal work was done according to the ARRIVE guidelines (Kilkenny et al., 2010) under project licenses P4B738A3B and
P8484EDAE. RT112 bladder cancer xenografts were established by implanting 100 mL (5 3 106) cells with Matrigel (1:2 ratio of Ma-
trigel and cold PBS with cells) subcutaneously into the flank of CD-1 nude mice. Mice were randomized to the following treatment
groups using the ‘‘random’’ function on Excel: control (no treatment), 25mg/kg CB-5083 (diluted in 5%DMSO, 0.5%methylcellulose
and 1% Tween-80 in ddH2O) via intraperitoneal injection, radiotherapy only (6 Gy, single fraction) and radiotherapy combined with
CB-5083, where the drugwas administered 6 hours before radiotherapy. Treatmentswere initiatedwhen tumor size reached 50mm3.
Tumor progression was monitored trice weekly with callipers, by the width, height and length x p/6. Kaplan-Meier survival analyses
were used tomeasure the time to treble tumor volume in CD-1 nudemice, and statistical significance (p < 0.05) was determined using
the Mantel-Cox test.
Pharmacokinetic analysis of CB-5083 concentration
Tumor cell xenografts were established in CD-1 nude mice as above. Treatment was given once tumors reached 50mm3. Mice were
treated at 25 mg/kg CB-5083 via intraperitoneal injection for 6 hours, and plasma, bladder, kidney, liver and tumor were collected to
determine the concentration of CB-5083 (mM) by high performance liquid chromatography (HPLC) analysis.
Colony formation assay
Cells were seeded at appropriate densities in triplicate and irradiated with 0, 2, 4, 6 and 8 Gy. Cells were cultured for 8-10 days to
allow colonies to form. Colonies were fixed and stained with 0.5% crystal violet in dH2O and 20% methanol for 5-10 minutes. Col-
onies were counted manually or by using GelCount colony counter (Oxford Optronix). The surviving fraction was determined by
normalizing the number of colonies in each condition to the unirradiated control. For drug-only clonogenic assays, cells were normal-
ized to DMSO control. All experiments were conducted in triplicate across technical replicates.
Immunofluorescence microscopy and irradiation
Cells cultured on 10 mm No. 1 cover glasses (VWR) were pre-sensitized in complete medium containing 10 mg/mL Hoechst 33342
20minutes prior to lasermicro-irradiation or ionising radiation. S phase cells weremarked by treatmentwith 10 mMEdU for 20minutes
before DNA damage induction, after whichmedium containing drugs was replaced with fresh completemedium. For lasermicro-irra-
diation, cells were irradiated using 355 nm pulsed laser connected to a Nikon TE2000 microscope. For ionising radiation, cells were
irradiated at a dose rate of 1.5 Gy/min using Gamma-Service Medical GmbH GSR D1 irradiator. Cells were allowed to recover for
indicated times prior to permeabilisation with 0.3% Triton X-100 for 10 minutes at room temperature (RT). Cells were fixed with
ice cold 4%PFA in PBS for 15minutes at RT, and samples were blocked by incubation in 5%BSA in PBS for 1 hour at RT or overnight
at 4C. Incubation with indicated primary and secondary antibodies was done in 2.5% BSA in PBS for 1 hour at RT, and coverslips
weremounted onmicroscopy slides usingmounting reagent with DAPI (Invitrogen). For laser micro-irradiation experiments and RPA,
gH2AX, MRE11, 53BP1, REV7, RAD51 and RAD52 foci, soluble proteins were pre-extracted with 25 mM HEPES (pH 7.4), 50 mM
NaCl, 1 mM EDTA, 3 mMMgCl2, 300 mM sucrose and 0.5% Triton X-100 for 3-5 minutes on ice. Fluorescent foci and laser-induced
damage areas were imaged using a Nikon Ni-E epifluorescent microscope under a 60X objective (for Figures S2 and S4) or Zeiss 710
confocal microscopy using either a 40X or 63X objective (for all the rest of the figures). All microscopy images were analyzed with FIJI
(ImageJ) software.
BrdU foci detection without denaturation
Cells cultured on 10 mm No. 1 cover glasses (VWR) were incubated with 10 mM BrdU for 24 hours to visualize single-stranded DNA.
Cells were treated with 10 mM CB-5083 or 100 mMMirin for the last 2 and 3 hours, respectively. Ten mM EdU was added 20 minutes
prior to fixation tomark S phase. Cells were pre-extracted as above, fixed and the number of BrdU foci imaged using epifluorescence
microscopy. For siRNA treatments, cells were treated with siRNA for 48 hours total using RNAiMAX as mentioned. BrdU was added
to cells in the last 24 hours before harvesting.
Immunohistochemistry and H&E staining
Primary antibody for p97/VCP was diluted at 1:2,000 in 3% BSA and incubated overnight at 4C, followed by biotinylated secondary
antibody (Vector) for 15minutes at RT. Slides were counterstainedwith hematoxylin. Immunostaining was scanned using 40Xmagni-
fication with the Aperio ScanScope CS2 scanner and images were captured using Leica Aperio Image Scope software. Tissue arease5 Cell Reports 35, 109153, May 25, 2021
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OPEN ACCESSwere outlined by a consultant histopathologist (LB), JohnRadcliffe Hospital, Oxford. Staining intensity was determined independently
by two observers (SK+AK): 0 (negative), 1+ (weak), 2+ (moderate), 3+ (strong). Both scorers used reference images with typical
scoring values to determine the intensity of each area, and an overall consensus score was reached.
Cellular fractionation
Cells were fractionated as described previously (Méndez and Stillman, 2000). In brief, the cytoplasmic fraction was isolated by sus-
pending cells in buffer A (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2 2, 0.34 M sucrose, 10% glycerol) freshly supplemented with
protease and phosphatase inhibitors, NEM and 0.1% Triton X-100. Nuclei were ruptured to release the nucleoplasm using hypotonic
buffer B (10mMHEPES, 3mMEDTA, 0.2mMEGTA, pH 8.0). The chromatin was washed with benzonase buffer (25 mMTris-HCl, pH
8.0, 20 mM NaCl, 2 mM MgCl2) and digested with benzonase (500 U/ml) while rotating at 10 rpm for 30 min at room temperature.
Protein concentrations were measured using the RC DC Protein Assay kit (BioRad).
Immunoblot
Cell lysates were denatured by boiling in Laemmli sample buffer, separated by SDS-PAGE and transferred (Bio-Rad Trans-Blot Turbo
system or wet transfer) to 0.2-mm nitrocellulose membrane. Membranes blocked with Odyssey blocking buffer (Li-Cor Biosciences)
or 5%milk for 1 hour at room temperature. Membranes were incubated overnight with primary antibodies (Li-Cor antibody diluent or
5% BSA in TBS-T, pH 7.4). Membranes were washed three times with PBS-T (0.1% Tween-20) and incubated with secondary an-
tibodies (IRDye800 or 700CW secondary antibodies or secondary antibodies coupled to HRP) for 1 hour at room temperature. After
three additional washes with PBS-T, membranes were detected using a LI-COR Odyssey Fc (LI-COR Biosciences) or ECL-based
chemiluminescence with Bio-Rad gel imaging system.
Protein co-immunoprecipitation (Co-IP)
Cellswere transfectedwith the plasmidsof interest usingFuGENEHD transfection reagent (Promega; #E2311) and allowed to express
for 20 hours. In case of doxycycline (DOX)-induced expression of Strep-p97-EQ, cells were treated with DOX (1mg/ml) for 18 hours to
induceprotein expression. Cellswere then treatedwithDMSO/CB-5083 (10 mM for 4 hours) and/or IR (10Gywith 2-3 hours of recovery).
Cells were harvested by trypsinisation and rinsed twice with ice-cold PBS. Chromatin fraction was isolated as described above and
digestedwith benzonase andRNase at 4C, 15 rpm for 2 hours. Digested chromatinwas centrifuged at 10,000 x g, at 4C for 10minutes
and clear supernatant was transferred into a new tube. Supernatant was diluted 2-3 times with IP buffer (50 mM Tris-HCl pH 7.4;
150 mM NaCl; 1 mM EDTA; 0.5% Triton X-100; 20mM NEM; protease and phosphatase inhibitors) and incubated with pre-washed
anti-HA magnetic beads (Thermo Fisher; #88836) or MagStrep ‘‘type3’’ XT beads (IBA LifeSciences; #2-4090-002). IP was performed
according to the manufacturer’s protocol. Proteins were eluted in Laemmli sample buffer (2X) and analyzed by Western Blotting.
In case of endogenous p97 Co-IP, HEK293 cells were treated as indicated and fractionated to isolate chromatin. The chromatin
fraction was digested as above and diluted 2 times with IP buffer (50 mM Tris-HCl pH 7.4; 150 mMNaCl; 1 mM EDTA; 0.1% Triton X-
100; 2 mMMgCl2; 20 mM NEM, protease and phosphatase inhibitors). The diluted sample was used as input and incubated at 4
C,
15 rpm first with p97 (Proteintech; #10736-1-AP) or control IgG (non-commercial/KR Lab) antibodies for 1-2 hours and then with pro-
tein A magnetic beads (NEB; #S1425S) for another 2 hours. IP was performed according to the manufacturer’s protocol. Proteins
were eluted in Laemmli sample buffer (2X) and analyzed by Western Blotting.
MRE11 pull-down for mass spectrometry analysis
For mass spectrometry of MRE11 interactome, T24 cells were plated on 15 cm plates and transfected with 20 mg pCDNA3.3 vector
containing HA-MRE11 per plate, with FuGene transfection reagent in a 1:3 ratio. Cells were treated with 5 Gy IR in a cesium-137
Gamma-Service Medical GmbH GSR D1 irradiator and recovered for 4 hours. Cells were harvested and lysed in 50 mM HEPES
pH 7.5, 100mMNaCl, 10 mMEDTA, 1%w/v Triton X-100, 4 mM sodium pyrophoshate, 2mM sodium orthovanadate, 10mM sodium
fluoride, 50 mM b-glycerophosphate and Roche Complete Mini Protease inhibitor cocktail. Cell lysate was incubated with a mixture
of 25 mL protein A and 25 uL protein G dynabeads which were pre-washed with lysis buffer for 1 hour to pre-clear sample. HA-con-
jugatedmagnetic beads (Pierce) were also washed in lysis buffer, and sample incubated with these beads at 4C for 1 hour with rota-
tion. Beads were then washed six times with lysis buffer as above but containing 0.5 M NaCl instead of 100 mM NaCl. Elution was
carried out with HA peptide (2 mg/mL), 20-100 mL for 2 hours at room temperate. After elution, protein was precipitated using chlo-
roform/methanol, then trypsin digestion was carried out (Fischer et al., 2012).
Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC)/mass spectrometry (MS)
For quantitative Mass-Spectrometry, Flip-In T-Rex HEK293T/p97-E578Q-Strep cell lines were first SILAC labeled. After induction of
p97-E578Q-Strep with doxycycline (DOX) and treatment with 10 Gy of IR, nuclear/chromatin fractions were extracted, treated with
benzonase, and the p97 interactors in this fraction were pulled down with Strep-TACTIN beads (IBA).
Sample preparation and analysis by mass spectrometry
Pulled down proteins were reduced, alkylated and then precipitated using chloroform/methanol protein precipitation (Fischer et al.,
2012). Protein precipitates were solubilised in 6 M urea in 100 mM Tris pH 7.4, digested with trypsin (overnight at 37C; Promega),Cell Reports 35, 109153, May 25, 2021 e6
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OPEN ACCESSde-salted using C18 Sep Pak column cartridges (Waters, Milford, MA, USA) and dried using a speed vacuum. Peptides were resus-
pended in water with 0.1% trifluoroacetic acid (TFA) and 2% acetonitrile.
MRE11 pulled down tryptic peptides were analyzed by nano-ultra performance liquid chromatography tandemmass spectrometry
(UPLC-MS/MS) using a Waters nanoAcquitiy UPLC system connected to a LTQ Orbitrap Velos mass spectrometer (Thermo), as
described previously (Fischer et al., 2012). In brief, tryptic peptides were separated on a C18 reverse-phase column (Waters, nAcq-
uity, 75mmx 25cm, 1.7mmparticle size) using a multistep gradient from 1 to 40% acetonitrile in 60min at a flow rate of 250 nl/min. Full
MS scans were acquired over the m/z range of 300 – 1500 at 60000 resolution. MS/MS data was acquired in a data dependent
manner by selecting the top 20 most abundant precursor ions for CID fragmentation (Collision energy of 35). Proteins were identified
in MASCOT (v2.3), using the Human UniProt_SwissProt database (retrieved 20150204; containing 20,274 sequences). MASCOT
data results were filtered by applying a significance threshold at p < 0.001. The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD016279 (Perez-Riv-
erol et al., 2019).
p97 pulled down tryptic SILAC labeled peptides were analyzed by nano-UPLC-MS/MS using a Dionex Ultimate 3000 nano-UPLC
coupled to a Q-Exactive mass spectrometer (Thermo Fisher Scientific), as described previously (Vaz et al., 2016). Peptides were
loaded onto a trap column (PepMapC18; 300mm x 5mm, 5mm particle size, Thermo Fischer) for 1 min at a flow rate of 20 ml/min
and separated on an EASY-spray column (75 mm X 500 mm, 2 mm particle size; Thermo Scientific) with a linear gradient from 2%
to 35% acetonitrile in 0.1% formic acid and 5% DMSO with a 250 nL/min flow rate in 60 min. Mass spectra were acquired in a
data-dependent top15 method with the automatic switch between full MS-scan and MS/MS. Full MS scans were acquired in the
Orbitrap withm/z range of 380–1800 and at a resolution of 70K (AGC target at 3e6 ions, maximum injection time of 100ms). Precursor
ions (charge state > = 2) were sequentially isolated in theQuad (m/z 1.6 window) and fragmented on the HCD cell (normalized collision
energy of 28%). MS/MS data was obtained in the Orbitrap at a resolution of 17500 with a maximum acquisition time of 128ms, an
AGC target of 1e5 and a dynamic exclusion of 27 s. SILACMS/MS data was analyzed using Proteome Discoverer (v1.4.0.288; Ther-
moFisher). Peptide and protein identification was performed against the human UniProt-SwissProt database (retrieved 20150204;
containing 20,274 sequences) using MASCOT (sequences) and subsequently SILAC ratios were determined using the Proteome
Discoverer software algorithm recommended settings. Results for RAD50 protein were selected for this study.
High performance liquid chromatography (HPLC) analysis
CB-5083 calibration standards were prepared in control mouse plasma. Tissue samples were defrosted, weighed and homogenized
in deionised water giving a five-fold dilution. Plasma samples were used without dilution. Aliquots of each sample or standard was
taken and Gefitinib added as internal standard prior to extraction using ethyl acetate. Samples were dried down and reconstituted in
mobile phase for analysis.
Separation was performed on a Waters Alliance e2695 with a Waters X-Bridge C-18 3.5 mm 2.1 3 50 mm column. Analytes were
detected using a Waters Acquity QDa mass detector monitoring m/z 414.5 for CB 5083 and m/z 447.2 for Gefitinib in positive ion
mode. Mobile phase A was 10 mM ammonium formate pH 9.7, mobile phase B was acetonitrile. A gradient at 0.4 mL/min of
35%–90% B was run over 2 minutes with a total run time of 6 minutes.
Reporter assays
To measure homologous recombination (HR) efficiency, 5x105 U2OS DR-GFP cells were seeded in 6-well plates. Cells were treated
with indicated siRNAs and transfected the following day with 4 mg of I-SceI plasmid (gift from Dr. Timothy Humphrey, University of
Oxford) using Lipofectamine 3000 as per manufacturer’s instructions (Invitrogen). For CB-5083 treatment, cells were treated for 6
hours at 10 mMprior to I-SceI transfection. Cells were recovered in fresh complete media for at least 24 hours and GFP-positive cells
were determined using BD FACSDIVA software. The data were then normalized to I-SceI positive control and analyzed using FlowJo
V10. Statistical significance was determined using one-way ANOVA. To measure single-strand annealing (SSA) efficiency, 5x105
U2OS SA-GFP reporter cells were seeded in 6-well plates. Cells were transfected, treated and analyzed exactly as for HR assay,
however siRAD52 was used as a positive control instead of siRAD51.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed using GraphPad Prism 8 software unless otherwise specified. The type of statistical test used
is indicated in figure legends. All data are representative of 3 independent experiments unless otherwise stated. Sample sizes are
included in the figure legends. A p value of p % 0.05 was considered statistically significant.e7 Cell Reports 35, 109153, May 25, 2021
